Executive brief
Third-party risk management in life sciences has become a board-level issue. Biotech, pharmaceutical, and medical device companies now rely on a growing network of SaaS vendors, cloud providers, CROs, CDMOs, data processors, consultants, and AI-enabled platforms. Every one of those external relationships can create value, but every one can also introduce cyber, compliance, operational, and data integrity risk.
That is why organizations are rethinking vendor oversight beyond annual questionnaires and static spreadsheets. As USDM outlines in Third-Party Risk Management for Life Sciences, modern programs need continuous visibility into vendor posture, not just a point-in-time check during onboarding.
In many industries, vendor failure is expensive. In life sciences, it can also affect patient safety, product quality, regulatory standing, intellectual property, and business continuity. A weak third party can expose validated environments, interrupt critical operations, or mishandle sensitive clinical and manufacturing data.
This is where the regulated context matters. Life sciences companies need vendor oversight that aligns not only to general cybersecurity good practice, but also to GxP expectations, privacy obligations, and operational controls that can stand up under inspection. USDM’s approach reflects that broader requirement by connecting security, compliance, and business resilience.
An effective TPRM program needs to go beyond checking whether a vendor has a policy library. It should evaluate how a third party handles sensitive data, secures integrations, governs subcontractors, supports auditability, and responds to incidents.
The biggest change in third-party risk management in life sciences is the move away from static, annual reviews. Vendors change constantly. They release new features, modify hosting models, add subprocessors, expand integrations, and adopt new AI capabilities. A questionnaire completed nine months ago may already be outdated.
That is why mature programs are adopting a continuous assurance model. USDM’s case study on Transforming Third-Party Vendor Risk Management at Enterprise Scale shows what this looks like in practice: layered monitoring, analyst-driven qualification, and scalable managed assessments instead of one-and-done review cycles.